Skip to content



Flory Muanda

Dr. Flory Tsobo Muanda is a Postdoctoral research fellow with the Institute for Clinical Evaluative Sciences (ICES) Kidney, Dialysis, and Transplantation (KDT) Ontario Provincial Program and the department of Epidemiology and Biostatistics at the University of Western Ontario. Flory ‘research program aims to reduce medications errors in patients with low kidney function. He conducts populations-based studies to inform safer prescribing practices for older adults with chronic kidney disease using routinely collected healthcare data in Ontario (one of the few jurisdictions worldwide with linked population-based kidney lab data). He also plans to conduct pragmatic trials to implement educational intervention in primary care setting to help primary care doctors to make fewer medication errors in patients with low kidney function. Flory ‘research interest also includes drug safety in pregnancy and drug-drug interaction population-based studies. Dr. Muanda’s background is diverse with an extensive experience in conducting health services research. He trained as a physician and worked as a clinical investigator on several randomized clinical trials.

Ruth Rennicks White

As a founding member of OMNI, Ruth has an extensive background in obstetrical nursing of over 35 years, business management and over 20 years of clinical research experience, which has been instrumental as the Research Manager for the Department of Obstetrics, Gynecology and Newborn Care at The Ottawa Hospital and the OMNI Research Group at the OHRI. She provides guidance and mentorship to the research team members and is instrumental in the development, implementation and progress of all protocols, and all fiscal aspects of the group. More recently Ruth has also assisted other groups, in the role of Acting Scientific Manager for BORN Ontario and then the Manager of Operations for the mHealth program and the CANImmunize app at The Ottawa Hospital.



Dan Chateau

Dan Chateau is a Research Scientist at the Manitoba Centre for Health Policy and an Assistant Professor in the Department of Community Health Sciences at University of Manitoba. He completed a PhD in Cognitive Psychology at the University of Western Ontario, and has conducted research at both MCHP, and as a consultant in the Biostatistics Consulting Unit in the Max Rady College of Medicine, Rady Faculty of Health Sciences. These positions provided a strong base in health services research and quantitative research methods. Dr. Chateau has worked on a broad range of projects for organizations as diverse as the Division Scolaire Franco-Manitobaine, WRHA, Manitoba Health, the Canadian Science Centre for Human and Animal Health, and with numerous clinicians, such as ICU specialists, pharmacists, nurses, and members of other departments at the University of Manitoba and beyond. In addition to contributing to numerous deliverables at MCHP, at present Dan is a member of the quantitative methods team for the Canadian Network of Observational Drugs Effect Studies (CNODES), and a co-PI on a large multi-year grant investigating the effects of policies and interventions on health equity in Manitoba’s children.

Sherif Eltonsy

Dr. Eltonsy is a pharmacoepidemiologist with an academic focus on drug safety and effectiveness and real-world evidence. He holds a Bachelor’s degree in Pharmacy and Master’s and PhD in Pharmaceutical Sciences, Epidemiology and Biostatistics from the Université de Montreal. He completed a Post-doctoral Fellowship at the Centre de formation médicale du Nouveau-Brunswick (Université de Sherbrooke and Université de Moncton) and worked as Pharmacoepidemiologist with the Maritime SPOR SUPPORT Unit (MSSU). Throughout his academic progress, Sherif accumulated numerous honors including the Rising-Star Award in two Canadian provinces. Dr. Eltonsy is a Research Scientist at the Children’s Hospital Research Institute of Manitoba (CHRIM), also a member of the Canadian Network for Observational Drug Effect Studies. Dr. Eltonsy main area of research is drug safety evaluation with a special focus on mother-infant health. The Eltonsy lab aims to provide clinically relevant evidence that improves prescribing standards for pregnant women and facilitate evidence-based decision-making by health professionals and policy makers.



Brandace (Brandy) Winquist

Brandy Winquist holds a Bachelor’s degree (hons) in Sociology and Master’s of Science in Community Health & Epidemiology from the University of Saskatchewan. She obtained her PhD in Community and Population Health Sciences in 2014, after completing a strategic training fellowship in the CIHR-funded Community and Population Health Research training program. Brandy has led and collaborated on research studies in the areas of maternal and child health, health services and population health. As an investigator in the Canadian Network for Observational Drug Effects Studies and the Saskatchewan lead for the Canadian Mother Child Cohort, she has co-lead multi-province studies investigating maternal-infant outcomes following prenatal exposure to prescription medications. Brandy is an adjunct professor in the College of Medicine at the University of Saskatchewan and a member of the Saskatchewan Health Authority’s senior leadership team providing oversight for the research, ethics, and academic health sciences departments. She is the Chair of the Saskatchewan Epidemiology Association. Brandy’s work within the health system has enabled her to cultivate expertise in areas of real-world evidence, medical ethics, and data systems. 



Padma Kaul

Dr. Padma Kaul is a Professor in the Department of Medicine, an Adjunct Professor at the School of Public Health, and Co-Director of the Canadian VIGOUR Centre at the University of Alberta, Edmonton, Alberta, Canada; and an Adjunct Professor in the Department of Population Health Sciences, Duke University, Durham, North Carolina. She holds a CIHR Sex and Gender Science Chair and a Heart & Stroke Chair in Cardiovascular Research. Dr. Kaul is an epidemiologist and policy analyst by training. One of her primary interests is looking at the burden of heart disease in women relative to men. She has expanded her interest in women’s health by developing a longitudinal pregnancy and birth cohort to study the downstream effects of pregnancy-related complications and medication use during pregnancy on the development of chronic disease in both the mother and the child. Dr. Kaul has extensive experience working with population-level administrative data, clinical registries, as well as large, multinational clinical trials using an integrated database that links inpatient, outpatient, and vital statistic databases to examine cardiovascular care in Canada.


British Columbia

Gillian Hanley

Dr. Gillian Hanley is an Assistant Professor in the department of Obstetrics & Gynaecology at the University of British Columbia. She is a CIHR New Investigator and Michael Smith Foundation Scholar. She obtained her BSc at Dalhousie University where she did a combined Honours in Biology and Economics, followed by a MA at McMaster University in Economics with a concentration in health economics. More recently, she completed her doctorate studies at UBC in the School of Population and Public Health. Her research focus combines her substantive interest in women’s health with her training in economics, health services research, and epidemiology to answer questions related to gynecologic cancer, primarily ovarian cancer prevention, as well as healthy reproduction and pregnancy.

Tim Oberlander

Dr. Tim Oberlander is a physician scientist whose work bridges developmental neurosciences and community child health. As a clinician, he manages complex pain in children and has a particular interest in managing pain in children/youth with developmental disabilities. As a researcher, his primary interest has been in studying how early life experiences shape stress/pain and related neurobehavioral outcomes during childhood. Dr. Oberlander’s work extends from molecular/genetic studies to population epidemiological studies that characterize neurodevelopmental pathways that reflect risk, resiliency and developmental plasticity. Outcome measures include studies of pain reactivity, attention, mood and executive functions across early childhood. The goal of Dr. Oberlander’s work is to understand how and why this happens.